Comparative Pharmacology
Head-to-head clinical analysis: CILOXAN versus ZYMAXID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CILOXAN versus ZYMAXID.
CILOXAN vs ZYMAXID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciprofloxacin, a fluoroquinolone antibiotic, inhibits bacterial DNA gyrase and topoisomerase IV, blocking DNA replication and transcription.
Gatifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, leading to inhibition of DNA replication and transcription.
1-2 drops in affected eye(s) every 2 hours while awake for 2 days, then every 4 hours for 5 days; or 1-2 drops 4 times daily for 7 days. Ointment: ½-inch ribbon into conjunctival sac 3 times daily for 2 days, then 2 times daily for 5 days.
1 drop of 0.5% ophthalmic solution in the affected eye(s) every 4 to 6 hours while awake for 7 days.
None Documented
None Documented
Terminal elimination half-life approximately 4 hours in patients with normal renal function; extended to 8-12 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 24 hours in severe impairment (CrCl <30 mL/min)
Terminal elimination half-life is approximately 2-4 hours in patients with normal renal function. In renal impairment, half-life may be prolonged up to 8-12 hours, requiring dose adjustment.
Renal: 50-70% unchanged drug; biliary: 15-20% as metabolites; fecal: 20-35%
Primarily renal excretion as unchanged drug (approximately 80-90% of administered dose). Minimal biliary/fecal elimination (<5%).
Category C
Category C
Fluoroquinolone Antibiotic (Ophthalmic)
Fluoroquinolone Antibiotic (Ophthalmic)